Updated:
Clean Biologics
Clean Biologics is a French family office investing in biopharma quality control, biosafety testing, and sterile manufacturing infrastructure.
Clean Biologics
Clean Biologics was established in France to invest behind the complex quality-assurance infrastructure that biologic drugmakers rely on to bring therapies to market. The firm concentrates on a niche and non-discretionary set of services: analytical testing, viral clearance studies, cleanroom microbiology, and sterile manufacturing support. These are the scientific checkpoints required by the FDA and EMA before a monoclonal antibody, cell therapy, or vaccine can be approved. The portfolio construction reflects a strategy of acquiring and building companies that function as the outsourced quality-control departments for large pharma sponsors and emerging biotech innovators. Asset classes in scope include direct private equity buyouts of established testing laboratories, balance-sheet commitments to build new cleanroom capacity, and selective co-investments alongside European healthcare funds. Geographic focus centers on France and select Western European markets where regulatory harmonization and a deep pool of scientific talent align with the firm's operational model. Public record indicates a history of backing CROs and CDMOs whose work is embedded in the late-stage development and commercial supply chains for biologic products. The firm maintains a lean presence with no disclosed external communications, consistent with a single-family office that originates deals through scientific networks rather than intermediary auction processes. The principals draw on backgrounds in pharmaceutical manufacturing, quality assurance, and laboratory operations to evaluate technical and regulatory risk. No recent public hiring announcements, fund close disclosures, or vehicle launches have been reported, suggesting a steady-state investment cadence that prioritizes operational involvement over rapid portfolio expansion. Structurally, Clean Biologics sits at the intersection of family-office patient capital and a deep science operating capability — a configuration that allows it to hold assets through the extended revenue cycles and deferred profitability curves that characterize regulated laboratory assets. This model contrasts with generalist private equity firms that may struggle to underwrite the scientific and compliance complexity at scale.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
France
City
—
Corporate office
France
Sector focus
Frequently asked questions
What is Clean Biologics' investment focus?
Clean Biologics concentrates on the quality-control and manufacturing enablement layer of the biopharmaceutical industry. The firm targets companies providing biosafety testing, viral clearance validation, cleanroom monitoring, and sterile manufacturing services — the outsourced laboratory infrastructure that supports biologic drug development and commercial production.
Does Clean Biologics invest outside of France?
The firm's headquarters and primary investment activity are based in France. Its mandate extends to Western European markets where comparable regulatory frameworks and access to specialized scientific personnel support its operational model. No investments outside of Europe have been publicly documented.
How does Clean Biologics source deals?
Clean Biologics relies on relationships within the pharmaceutical manufacturing and quality-assurance community rather than broad auction processes. The firm's principals evaluate opportunities using direct technical and regulatory expertise, sourcing through scientific networks and industry contacts rather than investment banks or intermediaries.
Is Clean Biologics a single-family office?
Available information indicates Clean Biologics operates with the structural characteristics of a single-family office. It maintains a low public profile, does not disclose external limited partners, and deploys capital with a long-duration, operationally intensive approach consistent with proprietary family capital.
How is the growing biosimilar and biologic pipeline relevant to Clean Biologics' strategy?
The firm invests in companies whose services grow in direct proportion to biologic and biosimilar development volume. As the global pipeline of monoclonal antibodies, cell therapies, and gene therapies expands, the demand for third-party biosafety testing, viral clearance, and sterile manufacturing support increases — a structural tailwind for the portfolio.
Who manages investment decisions at Clean Biologics?
Clean Biologics has not publicly disclosed the names of its investment committee members or managing principals. The firm's operational approach suggests leadership with direct experience in pharmaceutical manufacturing, quality assurance, and laboratory operations, though specific biographies remain private.
What types of assets does Clean Biologics avoid?
The firm's investment scope excludes speculative, pre-revenue biotechnology platform plays, as well as therapeutic asset-level investments. Clean Biologics does not invest in drug discovery, clinical development, or the intellectual property of specific molecules, maintaining a strict focus on laboratory services and manufacturing infrastructure.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: